Michael Jaharis
Co-Founder
Founder, Vatera Healthcare Partners

Mr. Jaharis is co-founder of Arisaph Pharmaceuticals Inc. and has served as a Director of the company since 2005. The Jaharis Family has committed the majority of the firm’s funding since inception. Mr. Jaharis also co-founded Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in December 2006 for over $4 billion. At Kos, Mr. Jaharis committed approximately $200 million of funding to develop and commercialize Niaspan® the most potent, patient-friendly drug that raises HDL cholesterol.

Prior to Kos, Mr. Jaharis was the President and Chief Executive Officer of Key Pharmaceuticals from 1972 until its merger with Schering-Plough Corporation in 1986. Mr. Jaharis developed and executed the strategies that allowed Key to grow from only a few small cough and cold products that aggregated less than $2 million in sales to $200 million in worldwide sales by 1986, including Theo-Dur, which was the best-selling asthma product in the U.S. at that time, and Nitro-Dur, a major advance in angina therapy. Prior to Key, from 1961 to 1972, Mr. Jaharis was with Miles Laboratories, last serving as Vice President of the Ethical Drug Division. Mr. Jaharis received his B.A. from Carroll College and his law degree from DePaul University.

Mr. Jaharis also serves as Trustee Emeritus of Tufts University in Boston; Chairman of the Board of Overseers for the School of Medicine, Tufts University; Member of the Columbia University Medical Center Board of Visitors; Member of the Board of Overseers of the Weill Cornell Medical College and Graduate School of Medical Sciences; Director of The Onassis Public Benefit Foundation (USA); and Vice Chairman of the Greek Orthodox Archdiocese of America.

Christopher Kiritsy
Co-Founder, President and Chief Executive Officer

Mr. Kiritsy, a co-founder, joined the Company as President and Chief Executive Officer in June of 2005 and has served as a Director since inception. Mr. Kiritsy is a seasoned entrepreneur, who possesses 20 years of unique business and technical experience, previously holding senior management positions in R&D, business development and finance. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played an integral role in building Kos from a small development organization into a highly profitable, 1,500 person, fully-integrated pharmaceutical company with annual sales approaching $1 billion. During his 10 year tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos' IPO, and spearheaded in excess of 10 corporate development transactions. He also played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®) and in delivering financial results that consistently exceeded Wall Street expectations. In 2005, Fortune Magazine ranked Kos the fastest growing pharmaceutical company and 6th fastest growing company overall in the United States.

Prior to Kos, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology, a private biotechnology company, where he co-authored several publications in scientific journals. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.

William Bachovchin, Ph.D.
Co-Founder, Executive Vice President and Chief Scientific Officer

Dr. Bachovchin serves as Executive Vice President and Chief Scientific Officer, and has been a Director since he co-founded the Company in 1999. Dr. Bachovchin is a leader in the areas of boronic acid chemistry and enzyme biochemistry. Dr. Bachovchin's work has led to the discovery of several candidate drugs and to the formation of Point Therapeutics, Inc., which was a publicly traded biotechnology company prior to its merger with DARA BioSciences, Inc. Dr. Bachovchin has published more than 80 peer reviewed journal articles and has been an invited speaker to numerous scientific conferences. Dr. Bachovchin is an inventor on 12 issued patents and on numerous pending patent applications covering a variety of novel drug compounds and methods of treatment.

In addition to his role at Arisaph, Dr. Bachovchin is a Professor of Biochemistry at Tufts University School of Medicine, where he has served as a faculty member for nearly 30 years. Dr. Bachovchin completed his postdoctoral work with J.D. Roberts at the California Institute of Technology and at Harvard Medical School. Prior to his postdoctoral work, Dr. Bachovchin received his Ph.D. in chemistry from the California Institute of Technology and his B.S. from Wake Forest University.

Kevin Ferro
Chairman
Chief Executive Officer Vatera Healthcare Partners, Ferro Capital LLC & Oikos Advisors LLC

Mr. Ferro became a Director of Arisaph in 2005 and was elected Chairman in March 2007. Mr. Ferro served as a Director of Kos Pharmaceuticals, Inc. prior to its acquisition by Abbott Laboratories in 2006. He is the Chief Executive Officer and Chief Investment Officer of investment advisory firms Vatera Healthcare Partners, Ferro Capital LLC and Oikos Advisors LLC. Previously, Mr. Ferro was the Global Head of Alternative Investment Strategies for Commerzbank Securities in New York and Frankfurt, Germany, from 1998 to 2001. Prior to Commerzbank, he worked at D. E. Shaw & Co. LP, an investment firm in New York City from 1994 to 1998, last serving as Vice President. Mr. Ferro has been a featured speaker at many financial conferences and has appeared numerous times as a guest speaker on CNBC's European Closing Bell, CNBC’s Squawk Box, and n-tv television programs. Mr. Ferro has a Bachelor of Arts with Honors degree in Government from Harvard University.

Robert Baldini
Consultant, Corporate Development

Mr. Baldini joined the Board in 2005 and currently serves as a consultant to Arisaph, assisting in corporate development matters. From 1996 through 2006, Mr. Baldini was Vice Chairman of Kos Pharmaceuticals, Inc. playing key operating roles in sales and marketing and business development. Until 2001, Mr. Baldini was Kos' Chief Sales and Marketing Officer, in which he was responsible for guiding the creation of the Company's sales and marketing departments as well as the product launch of Niaspan® and Advicor®. Prior to Kos, Mr. Baldini served Key Pharmaceuticals from 1982 to 1986 as Senior Vice President of Sales and Marketing. Following its acquisition by Schering-Plough, he continued with the Key Pharmaceuticals Division of Schering-Plough until 1995, last serving as its President.

Mr. Baldini's more than fifty years of pharmaceutical industry experience include senior management positions at Key, Ciba-Geigy and Pfizer. Additionally, he has been involved in the development, launch and management of 27 major products, including several innovative, best-selling drug delivery products, such as Nitro-dur, K-dur, and Imdur in the course of his career. In addition to performing services for Arisaph, Mr. Baldini currently serves as a Board Member for Ferring Pharmaceuticals and Dermworks. Mr. Baldini is currently a member of the Seton Hall University Board of Regents. He holds a B.S. degree from Seton Hall University and an M.B.A. from New York University.

Antonio M. Gotto, Jr., M.D.
Stephen and Suzanne Weiss Dean of Weill Medical College of Cornell University

Dr. Gotto is the Stephen and Suzanne Weiss Dean of Weill Medical College of Cornell University in New York, New York and joined the Board of Directors of Arisaph in 2006. He is also a professor of medicine. An internationally recognized authority on cardiovascular disease, Dr. Gotto was first named dean of Weill Cornell in 1997. During his previous tenure at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor, chairman of the Department of Medicine, Scientific Director of the DeBakey Heart Center and held the JS Abercrombie Professor Chair for Atherosclerosis and Lipoprotein Research. He also served as chief of the Internal Medicine Service at The Methodist Hospital in Houston.

In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I) and they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. Dr. Gotto has also played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk for heart disease. Dr. Gotto’s postgraduate work included doctoral studies at Oxford University in England, as a Rhodes Scholar, and residency training at Massachusetts General Hospital in Boston. Dr. Gotto received his M.D. and B.A. degrees from Vanderbilt University.

Kathryn Jaharis
President, Jaharis Family Foundation

Kathryn Jaharis Ledes has served as a Director of the company since 2007. Ms. Jaharis serves as President of the Jaharis Family Foundation which supports medical, arts, cultural, educational and religious institutions. Ms. Jaharis serves on the board of the Little Orchestra Society, is a strong supporter of the Children’s Museum of Manhattan, community groups and has had a personal long-term commitment to organizations for the disadvantaged, environment and community service. Ms. Jaharis, a jewelry and fashion designer, graduated Northwestern University.

Steven Jaharis, M.D.
Family Practitioner, Winnetka Family Medicine

Dr. Jaharis has served as a Director of the company since 2005. Dr. Jaharis has been a practicing physician since 1990 and currently serves as a family practitioner at Winnetka Family Medicine. Town and Country magazine has honored Dr. Jaharis by naming him one of the top family practitioners in the country. He serves on the Board of Overseers of Tufts University School of Medicine, Board of Managers of Haverford College and also served as a Director of Kos Pharmaceuticals, Inc., prior to its acquisition by Abbott Laboratories in 2006. Dr. Jaharis received his undergraduate degree from Haverford College, his medical degree from Tufts University School of Medicine, and completed his residency at Cook County Hospital in Chicago. Dr. Jaharis serves as a Director of the Jaharis Family Foundation.

John M. Leonard, M.D.
Vice President, Global Pharmaceutical Research and Development, Abbott Laboratories

Dr. Leonard has served as a Director since 2007. Dr. Leonard is Vice President, Global Pharmaceutical Research and Development at Abbott Laboratories. Previously, he served as vice president, Global Medical & Scientific Affairs. Since joining Abbott in 1992 as head of the antiviral venture in the Pharmaceutical Products Division, he has held several positions in the same division, including Divisional Vice President, Pharmaceutical Ventures, and Vice President, Global Pharmaceutical Development. Prior to joining Abbott, Dr. Leonard was senior director for clinical research at G.H. Besselaar Associates in Princeton, N.J. He is board certified in internal medicine and is licensed to practice in Illinois and Maryland.

Dr. Leonard is a member of many professional groups, including the American Society of Clinical Oncology. He serves on the science and regulatory affairs committees of PhRMA and is on the board of directors of the Biotechnology Industry Organization (BIO) and the National Association for Biomedical Research (NABR). Dr. Leonard earned a Bachelor's Degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from Johns Hopkins University in Baltimore, MD. Dr. Leonard completed an internship and residency in Internal Medicine at Stanford University Hospital followed by a postdoctoral fellowship in molecular virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Nicolaos E. Madias, M.D.
Chairman, Dept. of Medicine, Caritas St. Elizabeth’s Center

Dr. Madias joined the board in 2007. Dr. Madias currently serves as Chairman, Department of Medicine at Caritas St. Elizabeth’s Center and as a Professor of Medicine at Tufts University School of Medicine. Prior to his recent appointment at Caritas St. Elizabeth’s Center, Dr. Madias served as the Executive Academic Dean and Professor of Medicine at Tufts University School of Medicine (TUSM). Dr. Madias also served as Chief of the Division of Nephrology at the New England Medical Center from 1982 to 1999. He has served as an Established Investigator of the American Heart Association and as a member of the Internal Medicine and Nephrology Boards of the American Board of Internal Medicine. Dr. Madias is the author of more than 65 original publications and is a member of numerous scientific societies and editorial boards of professional publications, including co-editor of the Nephrology Forum of Kidney International, the official journal of the International Society of Nephrology. He is the recipient of many awards and honors, including several citations for excellence in teaching from TUSM and the Distinguished Faculty Award of TUSM.

Dr. Madias graduated from Athens University School of Medicine and completed his training in Internal Medicine at the Waltham-Weston Medical Center and the Caritas St. Elizabeth’s Medical Center. In Addition, Dr. Madias completed a clinical and research fellowship in Nephrology at Tufts-New England Medical Center (T-NEMC), the principal teaching hospital of TUSM.

Rex Roten, J.D.
Corporate Attorney, Roten Law Firm

Mr. Roten has served as a Director of the Company since 2005. Mr. Roten is an attorney who is admitted to practice in Florida, Texas and numerous Federal Courts. Mr. Roten currently practices in the area of corporate law with his firm, The Roten Law Firm Chartered, Clearwater, Florida. Prior to forming his own firm, Mr. Roten was a partner in the law firm of Livingston, Patterson, Strickland & Weiner, P.A. in Sarasota, Florida. Mr. Roten has published a number of articles in legal journals and is active in numerous philanthropic and professional endeavors. Mr. Roten graduated from Duke University with a degree in Economics and received his Juris Doctorate from the University of Miami School of Law in Coral Gables, Florida.

Mary T. Szela
Senior Vice President, Pharmaceutical Operations, Abbott Laboratories

Ms. Szela joined as a Director of the Company in 2007. Ms. Szela is Senior Vice President, Pharmaceutical Operations, leading Abbott’s commercial pharmaceutical business in the United States. Prior to her promotion in August of 2007, Ms. Szela served as Vice President, Commercial Pharmaceutical Operations, where she was responsible for sales and marketing of many of Abbott's pharmaceutical brands, including HUMIRA.

Ms. Szela joined Abbott in 1987 and has held several leadership positions at Abbott, including Vice President, Primary Care Commercial Operations, and Vice President of Hospital Business sector, in which she was responsible for anesthesia, acute care cardiovascular and pain management pharmaceuticals in Abbott's Hospital Products business (now Hospira). Prior to joining Abbott, she worked for the University of Illinois Hospital. Ms. Szela earned a Bachelor's Degree in Nursing and a Master's Degree in Business Administration from the University of Illinois.

David E. Wheadon, M.D.
Former Group Vice President, Global Pharmaceutical Regulatory Affairs, Abbott Laboratories

Dr. Wheadon joined Arisaph as a Director in 2007. Dr. Wheadon currently serves as Group Vice President, Global Pharmaceuticals Regulatory Affairs at Abbott Laboratories. Prior to Abbott, Dr. Wheadon was Senior Vice President of U.S. Regulatory Affairs at GlaxoSmithKline PLC. Prior to the merger between Glaxo-Welcome and SmithKline Beecham, he was with SmithKline Beecham where he held positions in SB Consumer Healthcare as Vice President and Director, CNS/GI. Dr. Wheadon began his industry career as an Associate Clinical Research Physician at Eli Lilly, where he was responsible for directing phase II-IV clinical trials of CNS compounds and for assessments of post-marketing surveillance data of marketed compounds, among other duties.

Along with being awarded an American Psychiatric Association-National Institute of Mental Health Fellowship, Dr. Wheadon has served on numerous boards and committees, has extensive publications, and maintains membership in several professional societies. Dr. Wheadon received his AB, cum laude, in Biology from Harvard College in 1979 and his MD from Johns Hopkins University School of Medicine in 1983. Following an internship in surgery, he completed his postgraduate training in Psychiatry at Tufts-New England Medical Center in 1987